4SC strengthens patent protection for its epigenetic cancer drug in China
Advertisement
4SC AG announced that it has further strengthened the patent protection for its epigenetic anti-cancer compound 4SC-202 - a selective inhibitor of LSD1 and HDACs 1, 2, and 3 - in China.
The Chinese Intellectual Property Office (SIPO) has granted a patent relating to the tosylate salt of the compound. As this salt has been used in the clinical trials with 4SC-202, this patent provides a further building block in 4SC's global protection strategy for the drug candidate. The patents for 4SC-202 tosylate salt will provide additional protection against potential competitors and thus complements the composition of matter patents for 4SC-202, which so far have been granted in 61 countries, including patents in the major markets USA, Europe, China, Japan, Russia, and India.